New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AKAM;ALKS;ABC;BT;DXCM;NKE;PANW;PINC;PSEC;TWTR;WCC;WMGI;AUY;LKQ;IMPV;CHRW;COP;HUBG;AOS;PNW;SWI;TITN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 >>
August 24, 2015
14:21 EDTPANW, IMPVJMP Securities says pullback in Palo Alto a buying opportunity
Subscribe for More Information
10:15 EDTWCCWESCO upgraded to Buy from Hold at Standpoint Research
Subscribe for More Information
09:45 EDTNKEOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Bank of America (BAC) upgraded to Outperform from Market Perform at Keefe Bruyette... Bristol-Myers (BMY) upgraded to Neutral from Underweight at Piper Jaffray... Chevron (CVX) upgraded to Neutral from Underperform at BofA/Merrill... Abercrombie & Fitch (ANF) upgraded to Overweight from Neutral... Nike (NKE) upgraded to Outperform from Market Perform at Telsey Advisory... DreamWorks (DWA) upgraded to Buy from Neutral at B. Riley... Caesarstone (CSTE) upgraded to Overweight from Equal Weight at Barclays... TransAlta (TAC) upgraded to Outperform from Market Perform at BMO Capital... Sarepta (SRPT) upgraded to Overweight from Neutral at Piper Jaffray... AutoZone (AZO) upgraded to Buy from Neutral at BofA/Merrill... Royal Dutch Shell (RDS.A) upgraded to Buy from Hold at Jefferies... Allscripts (MDRX) upgraded to Buy from Hold at Argus... China Unicom (CHU) upgraded to Buy from Hold at Jefferies... Ross Stores (ROST) upgraded to Buy from Neutral at Buckingham.
08:52 EDTPANWPalo Alto weakness creates buying opportunity, says JMP Securities
Subscribe for More Information
08:36 EDTPANW, IMPVIT security outlook still positive, says Pacific Crest
After attending a conference and analyzing IT security companies' Q2 results, Pacific Crest is more confident that IT security spending trends will continue to be strong. The firm identifies Barracuda (CUDA), Imperva (IMPV) and Palo Alto (PANW) as its favorite names in the space.
08:29 EDTDXCMWilliam Blair to hold a field trip
Subscribe for More Information
08:14 EDTAKAMAkamai management to meet with Oppenheimer
Subscribe for More Information
08:11 EDTALKSAlkermes delay for Aristada due to administrative issues, says Jefferies
Jefferies said it appears that the FDA's delay in approving Alkermes' Aristada is due to the agency's need for some additional review time. The firm said the fact that the FDA did not choose to issue a CRL letter gives it confidence that Alkermes should receive full approval in a "few weeks" and it maintains its Buy rating and $76 price target on the stock.
06:20 EDTNKENike upgraded to Outperform from Market Perform at Telsey Advisory
Subscribe for More Information
August 23, 2015
19:13 EDTBTBT executive says Verizon, AT&T abusing landline duopoly, FT reports
In a Financial Times interview published Sunday, BT Group's (BT) Americas president Bas Burger said Verizon (VZ) and AT&T (T) are abusing their control over telephone and broadband lines to charge inappropriate access fees to companies like BT. "For a western world country it is the worst I've seen... There is not sufficient regulation to create competition: almost all access is being provided by two companies and they have divided the country among themselves," remarked Burger, adding that the two companies are also not required to fix network problems within any specific timeframe. Reference Link
17:49 EDTCOPIran to increase oil production as BP, Shell express interest, Bloomberg says
Subscribe for More Information
August 21, 2015
16:01 EDTTWTROptions Update; August 21, 2015
Subscribe for More Information
16:01 EDTALKSAlkermes provides update on FDA review of ARISTADA
Alkermes announced that the U.S. FDA has advised Alkermes that it will not be able to complete its review of the New Drug Application for ARISTADA for the treatment of schizophrenia by the Prescription Drug User Fee Act action date of Aug. 22, 2015. The FDA indicated that this delay was expected to be brief, measured in terms of weeks, but could not confirm specific timing. The FDA also indicated that no additional data or information is required from Alkermes at this time. "We are confident in the ARISTADA program and our NDA submission, and we will work closely with the FDA as they complete their review," said Elliot Ehrich, M.D., Chief Medical Officer of Alkermes. "We look forward to bringing ARISTADA to market as a potential new treatment option to help address the significant unmet medical needs of patients living with schizophrenia."
13:38 EDTTWTRGoogle says brings tweets to mobile Google search app, desktop
In May, Google announced that it was bringing Tweets to Google Search on mobile devices. The company today updated the blog entry to say that it has "extended this to the desktop now, too, and in English everywhere." Reference Link
11:13 EDTTWTRStocks with call strike movement; AMZN TWTR
Subscribe for More Information
10:00 EDTTWTRTwitter volatility increases
Subscribe for More Information
09:59 EDTTWTRTwitter rises, levels to watch
Subscribe for More Information
09:34 EDTTWTRActive equity options trading on open
Active equity options trading on open: AAPL FB BAC NFLX DIS TSLA TWTR
09:29 EDTPANWPalo Alto results should beat expectations, says RBC Capital
Subscribe for More Information
08:32 EDTPINCPremier expands strategic partnership with Mercy Health
Mercy Health has expanded its partnership with Premier, Inc. to further advance population health management, with an increased focus on care for chronically-ill patients. The financial terms of the agreement were not disclosed.
1 | 2 | 3 | 4 | 5 | 6 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use